Effect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer Patients (QSYQT)

February 28, 2013 updated by: Chang Gung Memorial Hospital

Efficacy Study of Chinese Medicine on Modulating Immune Alterations in Advanced Stage, Non-small Cell Lung Cancer Patients Receiving 1st Line Doublet Chemotherapy and 2nd Line Target Therapy

The myeloid-derived suppressor cells (MDSCs) can further trigger cytotoxic T cell apoptosis, and may shift the macrophages toward M2 subtype, inhibit the Th1 cell, and initiate other immune suppressive mechanism. The functions of NK cells and regulatory T cells are altered, resulting in a disturbance of anti-tumor immune function. All these can further create an environment with a benefit for malignant cell growth and advancement. Astragalus-based formula may confer its survival advantage in cancer patients through modulating the immune system and reversing the immunosuppressive microenvironment.

The investigators aim to study the role of Qingshu-Yiqi-Tang in reversing the immune alterations in patients with advanced stage, non-small cell lung cancer who receive 1st line doublet chemotherapy of cisplatin plus doxetaxel（or Pemetrexed for adenocarcinoma）and 2nd line target therapy of erlotinib. The investigators can explore the possible mechanism of the Astragalus-based formula: Qingshu-Yiqi-Tang in modulating and reversing immunosuppression in advanced stage, non-small cell lung cancer patients.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Lung cancer is the leading cause of mortality and morbidity in the world. In Taiwan, lung cancer is the second cause of cancer death in men and the first in women. Although the five-year survival rate in the early stage, operable non-small cell lung cancer patients was ranged from 60% in stage IA patients to 15% in stage IIIA patients, over 85% of patients were of advanced and inoperable stage at diagnosis. Their medium survival was around six to nine months. New generations of chemotherapy or newly developed target therapy can significantly prolong the medium survival in statistics but the range is only one to three months, which is of limited significance in clinical practice, suggesting a limitation of current modalities of treatment. Chinese herbal medicines have a long history and show effectiveness in benefiting the maintenance of health and the recovery from diseases. Among them, Astragalus-based Chinese herbs have shown to increase effectiveness of platinum-based chemotherapy when combined with chemotherapy in advanced stage non-small cell lung cancer. Despite the fact that many Chinese herbal medicines have shown a pro-apoptotic effect on tumor cells in vitro, none of them have been demonstrated a tumorocidal effect in clinical practice, when used alone. Moreover, Astragalus has revealed an anti-apoptotic effect on cells, suggesting a non-tumorocidal function of Astragalus formula in benefiting cancer therapy.

Studies have shown that external or internal stimuli can induce cell transformation. As a result, dys-regulation in cell growth, DNA repair, cell proliferation and apotosis may occur. Normal committed tissue cells can transform into undifferentiated, multi-potential malignant cells. Normally, the competent immune system can recognize the transformed abnormal cells, undergo immune editing, activate cytotoxic cells to eradicate the abnormal cells and, finally, prevent malignant cell transformation. But through unknown mechanisms, the malignant cells may escape from immune surveillance, release chemokines, growth factors and other mediators to drive the change of inflammatory cells. Consequently, the anti-tumor function of immune cells is suppressed, leading to an environment in favor of development and metastasis of malignant cells. From the experiment of animal model and some observations on malignancy, researchers have suggested that malignant cells can release mediators, which can activate pre-myeloid suppressors and promote myeloid-derived suppressor cells development. The myeloid-derived suppressor cells can further trigger cytotoxic T cell apoptosis, and may shift the macrophages toward M2 subtype, inhibit the Th1 cell, and initiate other immune suppressive mechanism. The functions of NK cells and regulatory T cells are altered, resulting in a disturbance of anti-tumor immune function. All these can further create an environment with a benefit for malignant cell growth and advancement. Astragalus-based formula may confer its surval advantage in cancer patients through modulating the immune system and reversing the immunosuppressive microenvironment.

The lung cancer study in the Department of Thoracic Medicine has demonstrated that the myeloid-derived suppressor cells, cytotoxic T cells, Treg cells and monocytes play a critically important role in mediating immune alterations in patients with advanced stage, non-small cell lung cancer. In this three-year proposal, we aim to study the role of one Astragalus-based formula : Qingshu Yiqi Tang in reversing the immune alterations in patients with advanced stage, non-small cell lung cancer who receive 1st line doublet chemotherapy of cisplatin plus doxetaxel（or Pemetrexed for adenocarcinoma）and 2nd line target therapy of erlotinib. We will target on the modulating effect of Qingshu-Yiqi-Tang on the expression and function of myeloid-derived suppressor cells, Th1, Th2, cytotoxic T cells, NK cells, and the subtypes of monocytes (M1-like vs M2-like). Flow cytometry will be used to study the cell subtypes. The related cytokines and growth factors in serum or supernatant of culture, including IL4, IL-6, IL13, VEGF, TGFb, GM-CSF, will be analyzed using ELISA and FACS microbeads array. The expression of iNOS and arginase I will be verified using WB, IP and RT-PCR. The molecular mechanism related to the cell function will be studied using ex vivo cell co-culture model. All the patients will be followed up for three years at maximum. We hope that, via this three-year proposal, we can explore the possible mechanism of the Astragalus-based formula : Qingshu-Yiqi-Tang(清暑益氣湯) in modulating and reversing immunosuppression in advanced stage, non-small cell lung cancer patients. Through this study, we would found a basis for further comprehensive research on the mechanism of other Chinese herbal medicines for benefiting lung cancer therapy.

Study Type

Interventional

Enrollment (Anticipated)

120

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Taiwan
    • Taoyuan County
      • Gueishan Township, Taoyuan County, Taiwan, 33378
        • Recruiting
        • Center for traditional chinese medicine, Chang Gung Memorial Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients with pathological diagnosis of primary non-small-cell lung cancer Stage IIIB, IV
  2. Age ≧ 18 years
  3. Written, informed consent
  4. ECOG: 0-1

Exclusion Criteria:

  1. Subjects with inflammatory, infectious or immune disorder, such as TB, AIDS, active pneumonia, DM, SLE, rheumatoid disease.
  2. Subjects with systemic organ disease, such as CHF, ESRD, hepatitis, liver cirrhosis.
  3. Subjects with malignancy other than NSCLC.
  4. Subjects receiving anti-inflammatory or immunosuppressor medications, such as steroid (oral, except for chemotherapy premedication, or inhaled), NSAIDs.
  5. Patients with no willing to sign the informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SUPPORTIVE_CARE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Qingshu-Yiqi-Tang+standard therapy

Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy, maximal for 6 months.

1st line doublet chemotherapy: Cisplatin 70 mg/m2+Taxotere 60 mg/m2 D1/Q3W x 6 cycles, and then 2nd line target therapy: Erlotinib 150mg QD.
Drug: Astagalus-based Formula: Qingshu-Yiqi-Tang

Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy.

maximal for 6 months

Other Names:
  • Chuang Song Zong Pharmaceutical Co., Ltd. Taiwan.
  • CHING SHUU YIH CHIH TANG /QING SHU YI QI TANG
NO_INTERVENTION: 1st line doublet chemotherapy
1st line doublet chemotherapy: Cisplatin 70 mg/m2+Taxotere 60 mg/m2 D1/Q3W x 6 cycles, and then 2nd line target therapy: Erlotinib 150mg QD.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
overall survival
Time Frame: 3 years
3 years

Secondary Outcome Measures

Outcome Measure
Time Frame
Progression-free interval
Time Frame: 3 years
3 years

Other Outcome Measures

Outcome Measure
Time Frame
Quality of Life
Time Frame: 3 years
3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chang Gung Memorial Hospital

Investigators

  • Principal Investigator: Tse-Hung Huang, M.D., Chang Gung Memorial Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2009

Primary Completion (ANTICIPATED)

December 1, 2013

Study Completion (ANTICIPATED)

February 1, 2014

Study Registration Dates

First Submitted

February 27, 2013

First Submitted That Met QC Criteria

February 28, 2013

First Posted (ESTIMATE)

March 1, 2013

Study Record Updates

Last Update Posted (ESTIMATE)

March 1, 2013

Last Update Submitted That Met QC Criteria

February 28, 2013

Last Verified

April 1, 2009

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 97-1967A3

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Carcinoma, Non-Small-Cell Lung

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe